Pharmaceutical
Learn about the latest developments in the pharmaceutical cannabis industry with Business of Cannabis. Discover new drugs, research, and more.
Pharmaceutical · page 8
- Pharmaceutical
European Cannabis Stocks Review: Jazz Pharmaceuticals Fails Phase 3 Trail For Sativex, CiiTech Pushes Ahead With IPO Plans
Jazz Pharmaceuticals Jazz Pharmaceuticals, which has become the world’s largest exporter of medical cannabis products since it bought GW Pharmaceuticals for $7.2bn last year, saw its stock price rise this week despite news that its flagship product failed phase 3 trials.
- CBD Market
EFSA ‘Stopping The Clock’ On EU CBD Novel Foods Applications, But Doubts Remain Over Decision’s Impact In UK
THE European Food Safety Authority (EFSA) issued a statement last week announcing that its scientists ‘cannot currently establish the safety of cannabidiol (CBD) as a novel food’.
- CBD Market
Kolluda collaborates with Orange County CBD
The pair say they have a common passion for innovation.
- Pharmaceutical
European Cannabis Stocks Review: Yooma Wellness Reports More Losses In Q1, Chill Brands Stock Jumps 10% On Open Offer, & More from OCT
Yooma Wellness Just two weeks after publishing its delayed full-year results, in which it reported a $33m loss, Yooma Wellness has released its sales figures for the first quarter of 2022.
- CBD Market
Chaos in cannabis: is the Novel Foods process fit for purpose?
Chris Tasker of Global Cannabinoid Solutions explores cognitive bias, synthetic compounds, the endocannbinoid system and animal testing in cannabis.
- Pharmaceutical
Republican lawmakers are starting to change their tune on cannabis
MUSIC TO OUR EARS More Republican lawmakers are changing their tune on cannabis Shifting attitudes among Republicans toward cannabis are now mirrored in Congress, reports Forbes, where lawmakers are debating not if marijuana should be legalized, but how.
- Opinion
European Cannabis Industry ‘Potentially An Even Bigger Opportunity’ Than The US, And Investors Should ‘Wake Up To The Opportunities In Their Own Backyard’
NORTH American investment in the European cannabis industry has grown at pace over the last few years, with hundreds of millions in capital flooding into the region from across the Atlantic.
- Pharmaceutical
Roundup of Q1 2022 financial results in the UK medical cannabis space
Companies across the cannabis industry announce financial results for the first quarter of 2022, Cannabis Wealth rounds up the results of six major firms expanding within the UK medical cannabis space. 2021 was a positive year for cannabis businesses with 165 per cent year-over-year growth in cannabis equity capital raises and a series of high…
- CBD Market
How two former heads at Johnson & Johnson are bringing a science-based approach to CBD
Two former Johnson & Johnson executives teamed up in 2020 to bring their experience in consumer medical products to the CBD industry and create products that are more efficient and effective.
- Pharmaceutical
EU Cannabis Stocks Review: Love Hemp & Yooma Wellness Both See Their Shares Suspended
It has been another dramatic week on the global markets, with the Pound Sterling falling to a 2022-low and the NASDAQ registering its biggest one-day decline since June 2020 on continued fears of runaway inflation.
- Pharmaceutical
Jazz Pharma Backs Crackdown On UK CBD Industry Amid Inquiry Into UK Drug Law
YESTERDAY morning the Home Affairs Committee held the opening session of its new inquiry into drugs, seeking to examine the impact and efficacy of the ‘current legislative framework’.
- Pharmaceutical
Oxford Cannabinoid Technologies Announces Formation of Scientific Advisory Board to Support Clinical Strategy
OXFORD Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market is pleased to announce the formation of its Scientific Advisory Board (“SAB”).
